HC Wainwright & Co. Maintains Buy on Phio Pharma, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino maintains a Buy rating on Phio Pharma (NASDAQ:PHIO) but lowers the price target from $6 to $4.

February 06, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Phio Pharma but lowers the price target from $6 to $4.
While the maintenance of a Buy rating suggests continued confidence in Phio Pharma's potential, the reduction in the price target could indicate a reassessment of the company's near-term prospects or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as positive and negative factors balance each other out.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100